Welcome to our dedicated page for Cellyan Biotechnology Co. SEC filings (Ticker: HKPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellyan Biotechnology Co., Ltd. filings document the foreign private issuer’s OTC pharmaceutical cross-border e-commerce supply chain operations, public-company governance, and capital structure. Form 6-K reports include interim consolidated financial statements, operating and financial review materials, and disclosures related to the company’s Class A ordinary shares.
The filing record also covers annual general meeting materials, board and officer changes, independent director appointments, amended constitutional documents, an equity incentive plan, share repurchase and Class B ordinary share matters, Nasdaq minimum bid-price compliance notices, and financing arrangements involving units, warrants, and resale registration rights.
Cellyan Biotechnology Co., Ltd., a Cayman Islands holding company listed on Nasdaq as HKPD, reports on its year ended March 31, 2026. Operations run through Hong Kong subsidiaries and focus on OTC pharmaceutical cross-border procurement, distribution and supply chain services for e-commerce platforms serving Mainland China.
The business is highly concentrated, with seven customers each over 5% of revenue in 2026, including CaiNiao at 10.50%, and two key suppliers providing in total 41.08% of purchases. Management highlights intense competition, dependence on cross-border e-commerce demand, trade and tariff changes, warehouse disruptions, inventory risks, third-party logistics performance and complex licensing and compliance requirements in Hong Kong, Mainland China and internationally.
The report details political and regulatory uncertainty tied to PRC influence over Hong Kong (including the Hong Kong National Security Law), evolving U.S. rules such as the HFCA/AHFCA Acts that could affect U.S. trading, foreign-exchange exposure between HK$ and U.S. dollars, and reliance on dividends from Hong Kong subsidiaries. It also discloses material weaknesses in internal control over financial reporting, including insufficient IFRS/SEC expertise, lack of formal accounting manuals and inadequate approval processes for related-party transactions, with remediation initiatives underway.
Cellyan Biotechnology Co., Ltd reported that Nasdaq’s Listing Qualifications Staff has granted an additional 180 calendar day period, until January 11, 2027, to regain compliance with the Nasdaq Minimum Bid Price Requirement for continued listing.
To regain compliance, the company’s Class A ordinary shares must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days within this period. Nasdaq noted that Cellyan currently meets all other applicable listing standards, including market value of publicly held shares, but the company cautions there is no assurance it will ultimately satisfy the bid price requirement. The shares continue to trade on Nasdaq under the ticker HKPD.
Cellyan Biotechnology filed a Form F-3 shelf registration to offer up to $200,000,000 of Class A ordinary shares, debt securities, warrants, rights and units, to be sold from time to time after the effective date. The prospectus discloses a public float of $24.95 million (based on 34,181,490 shares held by non-affiliates) and states the Company may not sell a primary offering exceeding one-third of that public float under Form F-3 rules. The filing notes Nasdaq minimum bid price noncompliance with a compliance deadline of July 13, 2026, describes governance and operational risks from its Cayman/Hong Kong holding-company structure and summarizes PRC/Hong Kong regulatory and PCAOB inspection-related risks. Key corporate actions since the prior annual report are summarized, including management changes, an authorized capital increase and class conversion actions reflected in the amended memorandum and articles.
Cellyan Biotechnology Co., Ltd director CHAN Kam Leung filed an initial Form 3, which is a required insider ownership report when someone becomes a director or other reporting person. This filing lists their insider status with the company but shows no reported transactions or derivative positions.
Cellyan Biotechnology Co., Ltd director Wong Lap Sun has filed an initial Form 3 reporting beneficial ownership in the company. The filing shows direct ownership of 18,468 Class A Ordinary Shares as of the reported date, without any associated buy or sell transaction.
Cellyan Biotechnology Co., Ltd has an initial ownership report for Chief Strategy Officer Wang Zifeng under a Form 3 filing. The data shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this officer in the reported period.
Cellyan Biotechnology Co., Ltd filed an initial Form 3 for CFO Liu Shu. This filing identifies Liu Shu as an officer of the company but does not report any buy, sell, or other insider transactions, and shows no derivative positions or holding entries at this time.
Cellyan Biotechnology Co., Ltd filed an initial insider ownership report for director Zhou Mike Yao on Form 3. This filing identifies him as a director of the company and subject to insider reporting rules, but does not list any specific share holdings or recent transactions in the provided data.
Cellyan Biotechnology Co., Ltd director Wu Jingyan has filed an initial Form 3, which is the SEC’s statement of beneficial ownership for company insiders. This filing establishes Wu’s status as a director and provides a baseline disclosure of holdings, with no transactions reported in this data.